Potential and Pitfalls of Using Large Administrative Claims Data to Study the Safety of Osteoporosis Therapies
- 227 Downloads
Long-term bisphosphonate use may be associated with several rare adverse events. Such associations are not optimally evaluated in conventional randomized controlled trials due to the requirements of large numbers of patients and long-term follow-up. Alternatively, administrative claims data from various sources such as Medicare have been used. Because claims data are collected for billing and reimbursement purposes, they have limitations, including uncertain diagnostic validity and lack of detailed clinical information. Using such data for pharmacoepidemiologic research requires complex methodologies that may be less familiar to many researchers and clinicians. In this review, we discuss the strengths and limitations of using claims data for osteoporosis drug safety research, summarize recent advancements in methodologies that may be used to address the limitations, and present directions for future research using claims data.
KeywordsOsteoporosis medication Safety monitoring Claims data
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 18.National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis (2010).Google Scholar
- 20.• Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol. 2008;168(3):329–335. This article empirically demonstrated how immeasurable time bias can distort the results of a pharmacoepidemiologic study and evaluated the application of various methods to correct for the bias.PubMedCrossRefGoogle Scholar
- 21.Cramer J, Roy A, Burrell A. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(44–47).Google Scholar
- 26.• Virnig B, Durham SB, Folsom AR, Cerhan J. Linking the Iowa Women’s Health Study cohort to Medicare data: linkage results and application to hip fracture. Am J Epidemiol. 2010;172(3):327–333. This article presented the linkage of data from a conventional prospective cohort study to Medicare data and compared the data from the two sources with regard to the occurrence of hip fracture and postfracture mortality. The authors demonstrated that the incidences of both outcomes were underestimated using self-reported data.PubMedCrossRefGoogle Scholar
- 27.• St Peter WL, Liu J, Weinhandl ED, Fan Q. Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results. Hemodial Int. 2008;12(4):480–491. This article presented the linkage of data from multicenter, randomized, open-label trials to Medicare end-stage renal disease data. Significantly, 287 more deaths were identified using Medicare data that were not captured in the original trial.PubMedCrossRefGoogle Scholar
- 29.Narongroeknawin P, Patkar NM, Shakoory B, et al. Validation of diagnostic codes for subtrochanteric, diaphyseal, and typical hip fractures using administrative claims data. Arthritis Rheum. 2010;62(10 (supplement)):S1573.Google Scholar
- 32.Taylor AJ, Gary LC, Arora T, et al. Clinical and demographic factors associated with fractures among older Americans. Osteoporos Int. 2010.Google Scholar
- 36.• Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512–522. This article presented a multistep algorithm that identifies, prioritizes, and selects covariates to be used to construct a high-dimensional propensity score to adjust for confounding using administrative databases. The authors further applied and tested the algorithm in two separation studies and demonstrated that the algorithm performed better compared with using only predefined covariates.PubMedCrossRefGoogle Scholar
- 38.Kim SY, Schneeweiss S, Katz JN, et al. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2010.Google Scholar
- 46.FDA Approves Amgen’s XGEVA(TM) (Denosumab) for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Available at http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2010&releaseID=1498709.
- 47.Strom BL, Kimmel SE, editors. Textbook of pharmacoepidemiology. Chichester: Wiley; 2006.Google Scholar